Nonetheless, there is still hope in targeting BET as an anti-neoplastic strategy because of encouraging pre-clinical and early clinical evidence of the cytotoxicity of BET degraders in DLBCL [246]. Here, DNER is linked to diffuse large B-cell lymphoma.